- Conditions
- Non-muscle-invasive Bladder Cancer
- Interventions
- Gemcitabine, Docetaxel, Bacillus Calmette Guerin
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 229
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more
Location Directory
Clinical trials in Minneapolis, Minnesota
This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7879
Shown on this page
12
Current sort
Recently updated
Location scope
Minneapolis, MN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 949–960 of 7,879 matching trials in Minneapolis, MN.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Pain, Depression
- Interventions
- Computer game/task, Health surveys online
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Lyme Borreliosis
- Interventions
- VLA15, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 5 Years to 65 Years
- Enrollment
- 625 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 19
- States / cities
- Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Interventions
- Binimetinib, Encorafenib, Ipilimumab, Nivolumab
- Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 331
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 234 more
- Conditions
- Dermatomyositis
- Interventions
- Brepocitinib, Placebo
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 33 more
- Conditions
- Ovarian Cancer
- Interventions
- INCB123667
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Los Angeles, California • San Diego, California + 35 more
- Conditions
- Prematurity
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 28 Weeks to 34 Weeks
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Pembrolizumab, Olaparib, Carboplatin, Gemcitabine
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 25
- States / cities
- Monterey, California • San Francisco, California • Santa Monica, California + 20 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
- Procedure · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 262
- States / cities
- Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
- Conditions
- Stroke
- Interventions
- Transcranial magnetic stimulation (TMS)
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 24 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 27 more